TY - JOUR
T1 - Delivery of liposomes in dry powder form
T2 - Aerodynamic dispersion properties
AU - Desai, Tejas R.
AU - Hancock, Robert E.W.
AU - Finlay, Warren H.
N1 - Funding Information:
The authors wish to thank Austin Voss for his co-operation during the course of this study. WF gratefully acknowledges the financial support of the Canadian Cystic Fibrosis Foundation and the Natural Science and Engineering Research Council of Canada.
PY - 2003/12
Y1 - 2003/12
N2 - Objective: In our previous study, we reported a novel approach of delivering liposomes in dry powder form that relies on spontaneous formation of liposomes upon dispersion of micronised phospholipid(s) based powders in an aqueous environment, thereby creating reservoirs for the encapsulation of drugs [J. Pharm. Sci. 91 (2002) 482]. In this paper, we demonstrate the in vitro generation of aerosols from these novel powders. Methodology: Various formulations comprising different phospholipid(s) exhibiting different physico-chemical properties were prepared. Aerosol was generated using a deagglomeration rig wherein the powder was entrained at a flow rate of 60l/min and high turbulence was generated using air-jets. Two antimicrobial agents (ciprofloxacin and CM3, a novel peptide) and a bronchodilator, salbutamol sulfate, were used as model drugs to examine the powder dispersion properties. Results: The deagglomeration rig used in this study was able to disperse 87-95% of the total loaded powder into the cascade impactor. Amongst the various formulations comprising different phospholipid(s), DMPG and (DMPC+DMPG) based formulations exhibited excellent aerodynamic dispersion properties. Fine particle fractions (FPF) of more than 50% were achieved for these formulations for three model drugs. Encapsulation of the model drugs in the FPF, obtained upon dispersion of these novel powders, is also discussed in this paper. An encapsulation of approximately 35, 40 and 25% was achieved in the FPF for ciprofloxacin, CM3 peptide and salbutamol sulfate, respectively.
AB - Objective: In our previous study, we reported a novel approach of delivering liposomes in dry powder form that relies on spontaneous formation of liposomes upon dispersion of micronised phospholipid(s) based powders in an aqueous environment, thereby creating reservoirs for the encapsulation of drugs [J. Pharm. Sci. 91 (2002) 482]. In this paper, we demonstrate the in vitro generation of aerosols from these novel powders. Methodology: Various formulations comprising different phospholipid(s) exhibiting different physico-chemical properties were prepared. Aerosol was generated using a deagglomeration rig wherein the powder was entrained at a flow rate of 60l/min and high turbulence was generated using air-jets. Two antimicrobial agents (ciprofloxacin and CM3, a novel peptide) and a bronchodilator, salbutamol sulfate, were used as model drugs to examine the powder dispersion properties. Results: The deagglomeration rig used in this study was able to disperse 87-95% of the total loaded powder into the cascade impactor. Amongst the various formulations comprising different phospholipid(s), DMPG and (DMPC+DMPG) based formulations exhibited excellent aerodynamic dispersion properties. Fine particle fractions (FPF) of more than 50% were achieved for these formulations for three model drugs. Encapsulation of the model drugs in the FPF, obtained upon dispersion of these novel powders, is also discussed in this paper. An encapsulation of approximately 35, 40 and 25% was achieved in the FPF for ciprofloxacin, CM3 peptide and salbutamol sulfate, respectively.
KW - Cationic peptide
KW - Ciprofloxacin
KW - Liposome aerosol
KW - Liposomes
KW - Powder aerosol
KW - Salbutamol sulfate
UR - http://www.scopus.com/inward/record.url?scp=0344083495&partnerID=8YFLogxK
U2 - 10.1016/j.ejps.2003.09.008
DO - 10.1016/j.ejps.2003.09.008
M3 - Article
C2 - 14659490
AN - SCOPUS:0344083495
SN - 0928-0987
VL - 20
SP - 459
EP - 467
JO - European Journal of Pharmaceutical Sciences
JF - European Journal of Pharmaceutical Sciences
IS - 4-5
ER -